Non-Invasive Minimal Residual Disease (MRD) Assessment in Multiple Myeloma Via Functional Imaging and Liquid Biopsy
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY
The purpose of this study is to investigate the sensitivity and accuracy of non-invasive MRD assessment using liquid biopsy (blood draw) and functional imaging (whole body MRI) in participants with new diagnosed and previously treated multiple myeloma. The long-term goal of this study is to investigate whether non-invasive methods for MRD assessment can replace bone marrow aspiration and biopsy in a substantial percentage of participants with multiple myeloma.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Adults age ≥18 years
• Patients with newly diagnosed multiple myeloma
• Patients with previously treated multiple myeloma with a maximum of two prior lines of therapy
• Expected life expectancy of greater than one year and intention to start a new line of treatment
Locations
United States
New York
New York Presbyterian Hospital/Columbia University Irving Medical Center
RECRUITING
New York
Contact Information
Primary
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
Time Frame
Start Date: 2022-09-14
Estimated Completion Date: 2025-11
Participants
Target number of participants: 88
Treatments
Myeloma Group
Patients with newly diagnosed and previously treated multiple myeloma will receive bone marrow sampling and functional imaging.
Related Therapeutic Areas
Sponsors
Leads: Rajshekhar Chakraborty, MD
Collaborators: Hope Foundation